FY2020 · ended Dec 31, 2020 · Revenue $22.38M, +252.6% YoY · Filed Mar 3, 2022
Nextcure, Inc (NXTC) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $15.3 million in cash and investments and $4.7 million in total debt.
Revenue
$22.38M
+252.6% vs prior year
Net income
$-55.84M
-0.3% vs prior year
Operating cash flow (TTM)
$-36.98M
+31.7% vs year-ago TTM
Free cash flow
$-41.28M
+23.3% vs prior year
EPS
$-19.65
+17.7% vs prior year
Dividend per share
$0.00
Shares outstanding
3.56M
-87.3% vs prior year
Net cash
$10.59M
as of Jun 30, 2026
Operating margin
-184.2%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NXTC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Baltimore, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661059
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$57.6M | -$59.7M | -$67.6M | -$75.9M | -$70.8M |
| Net income | -$55.8M | -$55.7M | -$62.7M | -$74.7M | -$69.4M |
| Diluted EPS | -$19.65 | -$23.88 | -$2.25 | -$2.69 | -$2.51 |
| Operating cash flow | -$49.6M | -$40.8M | -$53.0M | -$53.9M | -$57.3M |
| Free cash flow | — | -$41.3M | -$53.8M | -$56.0M | -$59.6M |
| Total assets | $50.2M | $80.9M | $128.0M | $184.2M | $242.4M |
| Total liabilities | $15.2M | $15.4M | $13.6M | $16.6M | $9.0M |
| Stockholders' equity | $34.9M | $65.5M | $114.4M | $167.5M | $233.4M |
| Cash and investments | $26.0M | $27.7M | $13.1M | $26.6M | $12.3M |
| Total debt | $5.2M | $5.9M | $6.6M | $7.1M | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Sep 25, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 3, 2026 | Sep 3, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Exit or restructuring costs, Change in control, Officer or director change, Regulation FD disclosure, Other events
|
Jul 14, 2026 | Jul 14, 2026 |
All 394 Nextcure, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.